Patterns of Regional Spread for Esthesioneuroblastoma

Howell, Mark; Branstetter, Barton F.; Snyderman, Carl H.

doi:10.3174/ajnr.a2401

Cited by 63 publications

(67 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjuvant chemotherapy was performed with cisplatin and etopside, but without the subsequent proton radiaton used by Harvard University in a series of 9 patients, with good results (24). Although described as rare, retropharyngeal lymph node metastasis was considered as frequent in a study by Howell et al (25). Despite the absence of a central nervous system invasion, the patient in the present study showed a vertebrae lesion with somatostatin analogue uptake, highly suggestive of secondary involvement.…”

Section: A B C Dmentioning

confidence: 49%

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Sabongi

Gonçalves

Alves

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high. Treatment of neuroendocrine tumors using radionuclides bound to somatostatin analogues is well established in clinical practice. However, a standard and effective therapeutic approach has not been reported for ENB. The current study described the case of a 74-year-old female with numerous recurrences of ENB following multiple treatments and without possibility of resection. The patient was treated with the radiolabeled-somatostatin analogue, 177 Lutetium-DOTA-octreotate ( 177 Lu-DOTA-TATE), which successfully controlled the disease. This suggests that 177 Lu-DOTA-TATE is a potential treatment for ENB and may represent an effective alternative and novel therapeutic strategy for this disease.

show abstract

Section: A B C Dmentioning

confidence: 49%

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Sabongi

Gonçalves

Alves

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Although the standard PET/CT protocol at our institution uses low-dose, unenhanced CT, the addition of diagnostic CT with intravenous contrast material would likely result in detection of additional lesions and improved PET/CT performance, especially given that both primary esthesioneuroblastoma tumors and metastases show avid contrast enhancement (8)(9)(10). The role of PET/CT performed with full-dose contrastenhanced CT in esthesioneuroblastoma patients should be evaluated, including its performance compared with and in conjunction with MRI.…”

Section: Discussionmentioning

confidence: 99%

“…18 F-FDG PET/CT has proven to be a useful adjunct to conventional imaging in more common malignancies, leading to improved pretreatment staging, assessment of treatment response, and differentiation of early recurrence from therapy-induced changes. To date, MRI and CT have been the primary imaging modalities used for evaluation of patients with esthesioneuroblastoma (8)(9)(10)(11). Limited research has been performed on the role of 18 F-FDG PET/CT in esthesioneuroblastoma (12); the largest series to date included 12 patients having undergone PET/CT, and the modality was deemed appropriate for detecting cervical metastasis given their propensity for 18 F-FDG avidity (8).…”

mentioning

confidence: 99%

“…To date, MRI and CT have been the primary imaging modalities used for evaluation of patients with esthesioneuroblastoma (8)(9)(10)(11). Limited research has been performed on the role of 18 F-FDG PET/CT in esthesioneuroblastoma (12); the largest series to date included 12 patients having undergone PET/CT, and the modality was deemed appropriate for detecting cervical metastasis given their propensity for 18 F-FDG avidity (8). Therefore, our aim was to evaluate the clinical utility of 18 F-FDG PET in the diagnosis, staging, and restaging of esthesioneuroblastoma and to quantify the potential additional benefit of PET/CT to conventional imaging.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Added Value of ¹⁸F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma

Broski¹,

Hunt²,

Johnson³

et al. 2012

J Nucl Med

View full text Add to dashboard Cite

The purpose of this study was to evaluate the clinical utility of 18 F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. Methods: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. Results: Twenty-eight patients (mean age, 52.3 6 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 6 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 6 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P 5 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%) of 28 esthesioneuroblastoma patients. Of these, 10 (36%) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and distant metastases in 2 (7%) of 28, and distant metastases in 1 (4%) of 28. One patient (4%) was downstaged after negative findings on PET/CT. Conclusion: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.

show abstract

“…Although this tumour may occur in patients of any age, the literature points to a bimodal distribution, with peaks in the 2nd and 3rd decades and the 6th and 7th decades of life. 4 The Kadish staging system is applied to these tumours. 5 Stage A: disease confined to the nasal cavity Stage B: disease confined to the nasal cavity and paranasal sinuses Stage C: local or distant spread beyond the nasal cavity or sinuses The differential diagnosis of ENB includes the group of small round blue cell malignant neoplasms that can occur in the sinonasal tract, i.e.…”

Section: Histopathological Examination Gross Appearancementioning

confidence: 99%

Metachronous Primary Carcinomas of the Prostate and Urinary Bladder- Report of a Case With Review of Literature

N¹,

Suba²

2013

jemds

View full text Add to dashboard Cite

Esthesioneuroblastomas (ENBs) are undifferentiated tumours of neuroectodermal origin derived from the olfactory epithelium. Inconsistent histologic presentations can lead to the controversy regarding the exact histologic origin of ENBs, and this ambiguity can confound clinical and prognostic decisions. These tumours often display varying biologic activity ranging from indolent growth, with patient survival exceeding 20 years, to a highly aggressive neoplasm capable of rapid widespread metastasis, with survival limited to a few months. Due to the rare and complex nature of ENB, multiple opinions exist regarding the etiology, optimal staging system and treatment modalities. We have come across a case of Esthesioneuroblastoma, presenting as recurrent nasal mass with bleeding in a 50 yr old male. Histological presentation was unusual but the diagnosis was confirmed by Immunohistochemistry.

show abstract

Patterns of Regional Spread for Esthesioneuroblastoma

Cited by 63 publications

References 23 publications

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

The Added Value of ¹⁸F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma

Metachronous Primary Carcinomas of the Prostate and Urinary Bladder- Report of a Case With Review of Literature

Contact Info

Product

Resources

About

Patterns of Regional Spread for Esthesioneuroblastoma

Cited by 63 publications

References 23 publications

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

The Added Value of 18F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma

Metachronous Primary Carcinomas of the Prostate and Urinary Bladder- Report of a Case With Review of Literature

Contact Info

Product

Resources

About

The Added Value of ¹⁸F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma